SALT LAKE CITY, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that the Company is scheduled to give a presentation entitled: "Extensive 5-FU Inter-Patient Pharmacokinetic Variability May Result in Suboptimal 5-FU Dosing of Metastatic and Adjuvant Colon Cancer Patients on FOLFOX Regimens" on Sunday, January 24th, 2010, at the Seventh Annual Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
